Screener
Regenxbio RGNX Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: Regenxbio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336725
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Operating lease liabilities | 7,355 | 8,286 |
| Royalty monetization liabilities | 26,765 | 39,609 |
| Total current liabilities | 82,621 | 118,095 |
| Deferred revenue | 15,404 | 18,943 |
| Operating lease liabilities | 61,596 | 65,215 |
| Royalty monetization liabilities | 154,746 | 147,408 |
| Other liabilities | 486 | 638 |
| Total liabilities | 314,853 | 350,299 |
Item 1. Financial Statements.
FAQ
- What is Regenxbio's contract liabilities?
- Regenxbio (RGNX) reported contract liabilities of $15.4M in Q2 2026.
- How has Regenxbio's contract liabilities changed year-over-year?
- Regenxbio's contract liabilities decreased by 35.3% year-over-year, from $23.8M to $15.4M.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.
Ask your AI about Regenxbio's contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude